Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rezolute, Inc. (RZLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.19, with a market capitalisation of $409.24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $11.46. This page covers its latest market performance, valuation, price trends and company information.
$409.24M | |
$4.18 | |
$21.11 | |
$0.72 | |
$4.15 | |
2.00 | |
1.62M | |
-- | |
$11.46 | |
$1.07 | |
-- | |
-- |
Rezolute, Inc. (RZLT) is trading at $4.19 in pre-market trading as of 2026-09-16 08:45:00, up 0.84% ($0.03) from the previous close of $4.15
Pre-market trading shows how investors are pricing RZLT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Rezolute, Inc. (RZLT) moved from $4.58 to $4.19, representing a decline of 8.62% ($0.40).
The stock traded between $3.97 and $4.62 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 1.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30.0%
RZLT is currently trading at $4.19, placing it 30.0% of the way from its 52-week low of $1.07 to its 52-week high of $11.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rezolute, Inc. (RZLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.